The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder

Psychopharmacology

Volumn 210, Issue 1, 2010, Pages 13-24

  Albelda, Noa ^a   Bar On, Nitza ^a   Joel, Daphna ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Animal model; Extinction; NMDA; OCD (obsessive compulsive disorder); Post training signal attenuation; Rat

Indexed keywords

CYCLOSERINE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEEDBACK SYSTEM; MALE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR UPREGULATION; REINFORCEMENT; SIGNAL TRANSDUCTION; TASK PERFORMANCE;

ANIMALS; CYCLOSERINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTINCTION, PSYCHOLOGICAL; MALE; OBSESSIVE-COMPULSIVE DISORDER; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 77955569739     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1808-9     Document Type: Article

References (67)

1. Aboujaoude E, Barry JJ, Gamel N (2009) Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol 29:51-55
2. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
3. Aouizerate B, Guehl D, Cuny E, Rougier A, Burbaud P, Tignol J, Bioulac B (2005) Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder. Neuropsychiatr Dis Treat 1:231-243
4. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA (2004) Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 174:530-538
5. Baxter LR (1999) Functional imaging of brain systems mediating obsessive-compulsive disorder. In: Bunney CENW (ed) Neurobiology of Mental Illness. Oxford University Press, New York, pp 534-547
6. Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994) dcycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm Gen Sect 95:105-111
7. Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005) Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30:1735-1740
8. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58:424-428
9. Dall'Olio R, Gandolfi O (1993) The NMDA positive modulator Dcycloserine potentiates the neuroleptic activity of D1 and D2 dopamine receptor blockers in the rat. Psychopharmacology (Berl) 110:165-168
10. Dall'Olio R, Rimondini R, Gandolfi O (1994) The NMDA positive modulator D-cycloserine inhibits dopamine-mediated behaviors in the rat. Neuropharmacology 33:55-59
11. Denys D, Zohar J, Westenberg HG (2004) The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 65 (Suppl 14):11-17
12. Depoortere R, Perrault G, Sanger DJ (1999) Prepulse inhibition of the startle reflex in rats: effects of compounds acting at various sites on the NMDA receptor complex. Behav Pharmacol 10:51-62
13. Dolberg OT, Iancu I, Sasson Y, Zohar J (1996) The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol 19:129-147
14. Egashira N, Okuno R, Harada S, Matsushita M, Mishima K, Iwasaki K, Nishimura R, Oishi R, Fujiwara M (2008) Effects of glutamate-related drugs on marble-burying behavior in mice: implications for obsessive-compulsive disorder. Eur J Pharmacol 586:164-170
15. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL (1991) Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30:1167-1171
16. Flaisher-Grinberg S, Klavir O, Joel D (2008) The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder. Int J Neuropsychopharmacol 11:811-825
17. Friedlander L, Desrocher M (2006) Neuroimaging studies of obsessivecompulsive disorder in adults and children. Clin Psychol Rev 26:32-49
18. Gaisler-Salomon I, Weiner I (2003) Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology (Berl) 166:333-342
19. Gaisler-Salomon I, Diamant L, Rubin C, Weiner I (2008) Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology (Berl) 196:255-267
20. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF (1990) Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 51 (Suppl): 36-43, discussion 55-8
21. Grant P, Lougee L, Hirschtritt M, Swedo SE (2007) An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 17:761-767
22. Gray J (1982) The Neuropsychology of Anxiety: An Enquiry into the Functions of the Septo-hippocampal System. Oxford University Press, Oxford
23. Higgins GA, Enderlin M, Haman M, Fletcher PJ (2003) The 5-HT2A receptor antagonist M100, 907 attenuates motor and 'impulsivetype' behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berl) 170:309-319
24. Hood WF, Compton RP, Monahan JB (1989) D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91-95
25. Joel D (2006a) Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 30:374-388
26. Joel D (2006b) The signal attenuation ratmodel of obsessive-compulsive disorder: a review. Psychopharmacology (Berl) 186:487-503
27. Joel D, Avisar A (2001) Excessive lever pressing following posttraining signal attenuation in rats: a possible animal model of obsessive compulsive disorder? Behav Brain Res 123:77-87
28. Joel D, Doljansky J (2003) Selective alleviation of compulsive leverpressing in rats by D1, but not D2, blockade: possible implications for the involvement of D1 receptors in obsessivecompulsive disorder. Neuropsychopharmacology 28:77-85
29. Joel D, Klavir O (2006) The effects of temporary inactivation of the orbital cortex in the signal attenuation rat model of obsessive compulsive disorder. Behav Neurosci 120:976-983
30. Joel D, Avisar A, Doljansky J (2001) Enhancement of excessive leverpressing after post-training signal attenuation in rats by repeated administration of the D1 antagonist SCH 23390 or the D2 agonist quinpirole, but not the D1 agonist SKF 38393 or the D2 antagonist haloperidol. Behav Neurosci 115:1291-1300
31. Joel D, Ben-Amir E, Doljansky J, Flaisher S (2004) 'Compulsive' lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam. Behav Pharmacol 15:241-252
32. Joel D, Doljansky J, Roz N, Rehavi M (2005a) Role of the orbital cortex and of the serotonergic system in a rat model of obsessive compulsive disorder. Neuroscience 130:25-36
33. Joel D, Doljansky J, Schiller D (2005b) 'Compulsive' lever pressing in rats is enhanced following lesions to the orbital cortex, but not to the basolateral nucleus of the amygdala or to the dorsal medial prefrontal cortex. Eur J NeuroSci 21:2252-2262
34. Johnson JW, Kotermanski SE (2006) Mechanism of action of memantine. Curr Opin Pharmacol 6:61-67
35. Kanahara N, Shimizu E, Ohgake S, Fujita Y, Kohno M, Hashimoto T, Matsuzawa D, Shirayama Y, Hashimoto K, Iyo M (2008) Glycine and D:-serine, but not D:-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl) 198:363-374
36. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB (2007) D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 62:835-838
37. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6:869-872
38. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160-170
39. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150
40. Malloy P (1987) Frontal lobe dysfunction in obsessive compulsive disorder. In: Perecman E (ed) The Frontal Lobes Revisited. IRBN, New-York
41. McDougle CJ, Goodman WK, Leckman JF, Price LH (1993) The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis. Psychiatr Clin North Am 16:749-766
42. McGrath MJ, Campbell KM, Parks CR, Burton FH (2000) Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res 877:23-30
43. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
44. Monahan JB, Corpus VM, Hood WF, Thomas JW, Compton RP (1989) Characterization of a [3H]glycine recognition site as a modulatory site of the N-methyl-D-aspartate receptor complex. J Neurochem 53:370-375
45. Norberg MM, Krystal JH, Tolin DF (2008) A meta-analysis of Dcycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 63:1118-1126
46. Nordstrom EJ, Burton FH (2002) A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry. Mol Psychiatry 7 (617-25): 524
47. Otto MW (1992) Normal and abnormal information processing. A neuropsychological perspective on obsessive compulsive disorder. Psychiatr Clin North Am 15:825-848
48. Peterson SL, Schwade ND (1993) The anticonvulsant activity of Dcycloserine is specific for tonic convulsions. Epilepsy Res 15:141-148
49. Piccinelli M, Pini S, Bellantuono C, Wilkinson G (1995) Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 166:424-443
50. Pitkanen M, Sirvio J, MacDonald E, Niemi S, Ekonsalo T, Riekkinen P Sr (1995) The effects of D-cycloserine and MK-801 on the performance of rats in two spatial learning and memory tasks. Eur Neuropsychopharmacol 5:457-463
51. Pitman RK (1987) A cybernetic model of obsessive-compulsive psychopathology. Compr Psychiatry 28:334-343
52. Pitman RK (1991) Historical considerations. In: Zohar J, Insel T, Rasmussen S (eds) The psychobiology of obsessive-compulsive disorder. Springer, New-York, pp 1-12
53. Pittenger C, Krystal JH, Coric V (2006) Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 3:69-81 (Pubitemid 43276634)
54. Port RL, Seybold KS (1998) Manipulation of NMDA-receptor activity alters extinction of an instrumental response in rats. Physiol Behav 64:391-393
55. Priestley T, Kemp JA (1994) Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-Daspartic acid receptor complex. Mol Pharmacol 46:1191-1196
56. Reed GF (1977) Obsessional personality disorder and remembering. Br J Psychiatry 130:177-183
57. Sasson Y, Zohar J, Chopra M, Lustig M, Iancu I, Hendler T (1997) Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 58 (Suppl 12):7-10
58. Shannon HE, Love PL (2004) Within-session repeated acquisition behavior in rats as a potential model of executive function. Eur J Pharmacol 498:125-134
59. Starck G, Ljungberg M, Nilsson M, Jonsson L, Lundberg S, Ivarsson T, Ribbelin S, Ekholm S, Carlsson A, Forssell-Aronsson E, Carlsson ML (2008) A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J Neural Transm 115:1051-1062
60. Stein DJ (2002) Obsessive-compulsive disorder. Lancet 360:397-405
61. Stephens DN, Cole BJ (1996) AMPA antagonists differ from NMDA antagonists in their effects on operant DRL and delayed matching to position tasks. Psychopharmacology (Berl) 126:249-259
62. Szechtman H, Woody E (2004) Obsessive-compulsive disorder as a disturbance of security motivation. Psychol Rev 111:111-127
63. van der Meulen JA, Bilbija L, Joosten RN, de Bruin JP, Feenstra MG (2003) The NMDA-receptor antagonist MK-801 selectively disrupts reversal learning in rats. Neuro Report 14:2225-2228
64. Vengeliene V, Kiefer F, Spanagel R (2008) D-cycloserine facilitates extinction of conditioned alcohol-seeking behaviour in rats. Alcohol Alcohol 43:626-629
65. Welzl H, Berz S, Battig K (1991) The effects of the noncompetitive NMDA receptor antagonist MK 801 on DRL performance in rats. Psychobiology 19:211-216
66. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL (2008) Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 165:335-341
67. Zohar J, Zohar-Kadouch RC, Kindler S (1992) Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 43:210-218